Prof. Giuseppe Matarese MD,
Professor of Immunology
Dipartimento di Medicina Molecolare e Biotecnologie Mediche
Università di Napoli “Federico II”
Laboratorio di Immunologia
Napoli | Italia

Prof. Matarese, about 20 years ago, was among the first which opened a novel area of investigation that links nutritional status/metabolism to immune responses, currently known as “immunometabolism”. His paper that initiated the field and was published in Nature (1998), has been cited so far more than 2274 times. In that paper, Matarese and co-workers showed for the first time that leptin, the adipocyte-derived hormone that inhibits food intake and increases basal metabolism, can influence T helper 1 (Th1) immune responses. After that work, Prof. Matarese and co-workers went on demonstrating that leptin could influence susceptibility to multiple sclerosis (MS) and its animal model of experimental autoimmune encephalomyelitis (EAE) through the secretion of inflammatory cytokines (Matarese et al., JI, 2001; Sanna et al., JCI, 2003; Matarese et al., PNAS, 2005; De Rosa et al., JCI, 2006) and through the control on regulatory T (Treg) cell proliferation, suggesting for the first time a link between adipose tissue biology and Treg cell function (De Rosa et al., Immunity, 2007). Prof. Matarese also identified a novel link between “oscillations” of intracellular energy metabolism regulated by mTOR and the proliferation of Treg cells (Procaccini et al., Immunity, 2010) and the survival of effector T cells (Galgani et al., J. Immunol., 2010). In addition, Prof. Matarese showed that mTOR overactivation is responsible for the impaired proliferative potential in vivo and in vitro of human ex vivo isolated peripheral Treg cells from MS patients (Carbone et al., Nat Med. 2014). More recently, Prof. Matarese and co-workers identified a new mechanism of Foxp3 regulation linking engagement of glycolysis by Tconv cells in the generation of inducible (i)Treg cells through the enolase-1 enzyme (De Rosa et al. Nat. Immunol. 2015). This evidence has suggested for the first time that Treg cells not only rely on fatty acid metabolism, as generally thought, but also on glycolysis. Prof. Matarese confirmed the involvement of glycolysis in Treg cell immunobiology at the proteomic level (Procaccini et al. Immunity 2016), in the migration of Treg cells in peripheral tissues (Kishore et al. Immunity 2017), and in Treg cell expansion during tumour progression (Pacella et al. PNAS 2018). In the field of leptin biology and its use in human diseases, Prof. Matarese significantly contributed to the characterization of the effect of leptin in controlling food intake, metabolism and immune functions in humans (Farooqi et al. JCI 2002), in reconstituting CD4 T cell numbers (Matarese et al. PNAS 2013), and in restoring disturbed neuro-endocrine function in women with hypothalamic amenorrhoea (Chan et al. PNAS 2006; Chou et al. PNAS 2011). Further, Prof. Matarese contributed to the FDA and EMA approval of metreleptin (MYALEPT®, Aegerion Pharmaceuticals) for its use in humans in rare lypodistrophic subjects. He currently acts for the Advisory Committee in the strategic planning for the use of metreleptin in human diseases and the study of its immunogenicity.
For Grants, Prof. Matarese has been awarded an ERC-Grant (LeptinMS, n. 202579, ERC call 2007) in the first starting call which is ended in October 2011 (2008-2011, 40 months). Subsequently, Prof. Matarese has been awarded another 5 years ERC-Grant (menTORingTregs, n. 310496, ERC call 2012), which has been recently completed (2013-2018, 60 months; ended in April 2018). Both the awarded ERC-Grants represented a key step in the advancement of his career in the field of immunometabolism. In his career, Prof. Matarese has also received Grants from other National and International Grant Agencies including the Juvenile Diabetes Research Foundation (JDRF)-Telethon, European Foundation for the Study of Diabetes (EFSD), Italian Space Agency (ASI) and Italian Foundation for Multiple Sclerosis (FISM). Prof. Matarese acts as advisor and collaborates with International Pharma Industries such as Merck, Novartis and Biogen Idec, particularly in the context of characterization of the effects of novel drug treatments in multiple sclerosis.
Prof. Matarese has been invited as a speaker and/or chairman to more than 90 international conferences. Among them: Institute Pasteur, “Metabolic regulation of immune response”, Roma, 2018; 2013
CV Giuseppe Matarese
(2nd) and 2015 (3rd) Aegean-Nature Medicine “ImmunoMetabolism” Conferences, Rhodes, Greece; Keystone Symposia “Integrating Immunity and Metabolism”, Dublin, 2017; Hans-Fisher TUM Symposium “Metabolic principles of human physiology and disease”, Munich, 2015; Cold Spring Harbor Laboratory (CSHL) Expert Panel, Banbury Centre, 2012; Workshop Endocrine-Immunology, 2nd European Congress of Immunology, Berlin, 2009; 2008 Pennington Meeting, Neuro-Immuno-Endocrine signalling, Baton Rouge, USA, etc.
Finally, Prof. Matarese is an inventor in five patents on the use of leptin antagonists. Patents: 1) Patent on “Use of leptin, its derivatives, agonists and antagonists in modulating immune responses”, UK patent application n. GB9807062.6; 2) Patent on “Leptin antagonist and method for quantitative measurement of leptin”, EU patent n. 04797956.2-2402-EP2004013043. 3) Patent on “Leptin ligand” UK patent application n. GB0605162.7; 4) Patent on “Adjuvant” UK patent application n. GB0605163.5; 5) Patent on “A diagnostic assay for obesity and related disorders” UK patent application n. GB1004058.2 and US patent application n. US61/312,949; Pub. No.: WO/2011/117084, PCT/EP2011/053673.